Download

Full Text

12

CITATIONS

12 Total citations

0 Recent citations

2.15 Field Citation Ratio

0.47 Relative Citation Ratio

publications

0

supporting

0

mentioning

0

contrasting

0

Smart Citations

0

0

0

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003; 58: 335-341. (Pubitemid 38325707)
• Scheen AJ. Treatment of type 2 diabetes. Acta Clin Belg 2003; 58: 318-324. (Pubitemid 38017321)
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
• Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613. Erratum in: Ann Intern Med 2011; 155: 67-68.
• Lalau JD. Lactic acidosis induced by metformin: Incidence, management and prevention. Drug Saf 2010; 33: 727-740.
• Legrand D, Scheen AJ. Cumul de facteurs de risque et interactions médicamenteuses aboutissant á une acidose lactique sevére. Thérapie 2008; 63: 69-70.
• Hofkens P-J, De Winter S, Vanbrabant P. Metformin associated lactic acidosis (MALA): Case report. Acta Clin Belg 2011; 66: 390-392.
• McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005; 173: 502-504. (Pubitemid 41225045)
• Roussel R, Travert F, Pasquet B, et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899.
• Pilmore HL. Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010; 15: 412-418.
• Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc 2010; 50: 407-410.
• Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011; 4: 53-58.
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4: CD002967.
• Tsapas A. Therapeutics. Review: Metformin does not increase risk for lactic acidosis in type 2 diabetes. Ann Intern Med 2010; 153: JC1-9.
• Biradar V, Moran JL, Peake SL, Peter JV. Metformin-associated lactic acidosis (MALA): Clinical profile and outcomes in patients admitted to the intensive care unit. Crit Care Resusc 2010; 12: 191-195.
• Scheen AJ. Medications in kidney. Acta Clin Belg 2008; 63: 76-80.
• James A. Metformin and lactic acidosis. NSAIDs and renin-angiotensin- aldosterone system. BMJ 2009; 339: B5567. doi: 10.1136/bmj.b5567.
• Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254: 261-269.